
Please try another search
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
David Steven Cantor | - | 2016 | Chairman of Scientific Advisory Board (Currently Dormant) |
Evian Gordon | - | 2018 | Member of Scientific Advisory Board |
Emanuela Russo | - | 2018 | Chief Scientific Officer & Member of Scientific Advisory Board |
Tanju Surmeli | - | 2018 | Member of Scientific Advisory Board |
Gerald Quigley | - | 2022 | Director of Public Relations & Director |
Mark Davies | - | 2019 | Independent Non-Executive Chairman |
Anthony Filippis | - | 2025 | MD, CEO & Director |
Robert Maxwell Johnston | - | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review